PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.
Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z. · 2010
Read PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. by Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3220038.txt.
Description
Yan Zhang and colleagues tested blocking the immune checkpoint PD-L1 as a treatment for sepsis, in this 2010 mouse study in Critical Care. Sepsis can paralyze the immune system, partly through death of lymphocytes and failure of monocytes. The team induced sepsis in mice by puncturing the gut and measured checkpoint expression on immune cells a day later.
Septic mice carried more PD-1 and PD-L1 on their T cells, B cells, and monocytes than healthy controls. Giving an antibody that blocks PD-L1 significantly improved survival. Treated mice kept more of their lymphocytes, produced more of some inflammatory signals and less of a suppressive one, and cleared bacteria better. The authors propose PD-L1 blockade as a promising strategy against sepsis-driven immune suppression.
Catalog record
| CREATOR | Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |